• Something wrong with this record ?

Galectin-3 as an independent prognostic factor after heart transplantation

J. Franeková, L. Hošková, A. Jabor

. 2022 ; 36 (5) : e14592. [pub] 20220126

Language English Country Denmark

Document type Journal Article, Observational Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22018534

BACKGROUND: Galectin-3 (GAL3) is linked to the prognosis of patients with heart failure and after heart transplantation (HTx). We assessed the prognostic role of GAL3 in a long-term follow-up after HTx. METHODS: HTx patients (N = 121) were evaluated in a single-center, noninterventional, prospective, observational study. The median follow-up was 96 months (2942 days, interquartile range (IQR) 2408-3264 days), and 40 patients died. GAL3 was measured before HTx, +10 days after HTx, and during the first posttransplant year. Survival analysis (all-cause mortality) was performed with adjustments for clinical and laboratory variables. RESULTS: The median pretransplant GAL3 level was 18.0 μg/L (IQR 14.0-25.9), and higher values were associated with older age, worse kidney function, left ventricular assist device use before HTx, a higher IMPACT score, and mortality. Increased pretransplant GAL3 predicted shorter survival time (HR 2.05, 95% CI 1.09-3.85, p < .05). Similar prognostic power had GAL3 on the 10th posttransplant day (HR 2.03, 95% CI 1.08-3.82, p < .05). GAL3 was an independent predictor of death after adjustment for clinical variables (age, infection, diabetes, smoking, IMPACT score, and troponin). CONCLUSIONS: GAL3 was significantly associated with all-cause mortality after adjusting for clinical and laboratory variables and may serve as an additional prognostic biomarker.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018534
003      
CZ-PrNML
005      
20220804134835.0
007      
ta
008      
220720s2022 dk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ctr.14592 $2 doi
035    __
$a (PubMed)35029311
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a dk
100    1_
$a Franeková, Janka $u Department of Laboratory Methods, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u Third Faculty of Medicine, Charles University, Prague, Czech Republic
245    10
$a Galectin-3 as an independent prognostic factor after heart transplantation / $c J. Franeková, L. Hošková, A. Jabor
520    9_
$a BACKGROUND: Galectin-3 (GAL3) is linked to the prognosis of patients with heart failure and after heart transplantation (HTx). We assessed the prognostic role of GAL3 in a long-term follow-up after HTx. METHODS: HTx patients (N = 121) were evaluated in a single-center, noninterventional, prospective, observational study. The median follow-up was 96 months (2942 days, interquartile range (IQR) 2408-3264 days), and 40 patients died. GAL3 was measured before HTx, +10 days after HTx, and during the first posttransplant year. Survival analysis (all-cause mortality) was performed with adjustments for clinical and laboratory variables. RESULTS: The median pretransplant GAL3 level was 18.0 μg/L (IQR 14.0-25.9), and higher values were associated with older age, worse kidney function, left ventricular assist device use before HTx, a higher IMPACT score, and mortality. Increased pretransplant GAL3 predicted shorter survival time (HR 2.05, 95% CI 1.09-3.85, p < .05). Similar prognostic power had GAL3 on the 10th posttransplant day (HR 2.03, 95% CI 1.08-3.82, p < .05). GAL3 was an independent predictor of death after adjustment for clinical variables (age, infection, diabetes, smoking, IMPACT score, and troponin). CONCLUSIONS: GAL3 was significantly associated with all-cause mortality after adjusting for clinical and laboratory variables and may serve as an additional prognostic biomarker.
650    _2
$a krevní proteiny $7 D001798
650    12
$a galektin 3 $7 D037502
650    _2
$a galektiny $7 D037161
650    12
$a srdeční selhání $x diagnóza $7 D006333
650    12
$a transplantace srdce $7 D016027
650    _2
$a lidé $7 D006801
650    12
$a mortalita $7 D009026
650    _2
$a prognóza $7 D011379
650    _2
$a prospektivní studie $7 D011446
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hošková, Lenka $u Heart Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Jabor, Antonín $u Department of Laboratory Methods, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u Third Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000241443129
773    0_
$w MED00001167 $t Clinical transplantation $x 1399-0012 $g Roč. 36, č. 5 (2022), s. e14592
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35029311 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134829 $b ABA008
999    __
$a ok $b bmc $g 1822229 $s 1169777
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 36 $c 5 $d e14592 $e 20220126 $i 1399-0012 $m Clinical transplantation $n Clin Transplant $x MED00001167
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options